Update on grant-funded DR5 project

AI SummaryClose X

Fusion Antibodies plc has provided an update on its InnovateUK Launchpad grant-funded DR5 project, which aims to develop a humanised therapeutic antibody for treatment-resistant cancers. The company has successfully humanised the antibody using its CDRx® platform, developed complex structural variants showing positive results in tumour cell death assays, and created a stable cell line for large-scale manufacture using new microfluidic technology, reducing the timeline by approximately 50%. The project's completion date has been extended to December 31, 2026, with further pre-clinical evaluation planned. The total grant funding exceeds £808,000, with up to £545,000 available directly to Fusion for eligible costs including labour, overheads, and materials. This project has generated valuable case study data for Fusion's key technologies and has the potential to create a licensable therapeutic asset.

Disclaimer*

UK 100

Latest directors dealings